NIH-Funding

Notice of Correction to PAR-17-496, Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

NIH Funding Announcements - Fri, 10/13/2017 - 13:03
Notice NOT-CA-18-001 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Fundamental Science Research on Mind and Body Approaches (R21 - Clinical Trial Optional)

NIH Funding Announcements - Fri, 10/13/2017 - 12:58
Funding Opportunity PA-18-322 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages exploratory /developmental research grant applications (R21) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA.
Categories: NIH-Funding

Fundamental Science Research on Mind and Body Approaches (R01 - Clinical Trial Optional)

NIH Funding Announcements - Fri, 10/13/2017 - 12:58
Funding Opportunity PA-18-323 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications (R01) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA.
Categories: NIH-Funding

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)

NIH Funding Announcements - Fri, 10/13/2017 - 12:15
Funding Opportunity PAR-18-319 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive modeling of vaccine concepts in non-human primates may be included.
Categories: NIH-Funding

Minority-Patient Derived Xenograft (PDX) Development and Trial Center (PDTC) Network (U54)

NIH Funding Announcements - Fri, 10/13/2017 - 02:38
Funding Opportunity RFA-CA-17-032 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.
Categories: NIH-Funding

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)

NIH Funding Announcements - Fri, 10/13/2017 - 02:38
Funding Opportunity RFA-CA-17-033 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.
Categories: NIH-Funding

By: Jerry

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 22:52

Thank you very much!

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 21:33

Yes, you can send an abstract and/or specific aims for his/her take on whether the SRG is appropriate. If you are trying to decide between two study sections, you can note this as well. Your PO should have good insight on SRG choice, too.

>

Categories: NIH-Funding

By: Jerry

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 20:41

Hi, is it appropriate to ask the SRO if my proposal fits in his study section?

Thank you very much.

Categories: NIH-Funding

By: Unclear about ESI

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 17:52

Thank you very much for the information.

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 17:07

The NIH is operating under a continuing resolution (CR), which means their funding levels are 90% of what was approved for FY17. The interim paylines are always very conservative until the final federal budget passes, which for FY18 will not likely happen before December. Assuming the FY18 federal budget keeps funding levels at or above FY17 levels (right now, the NIH is looking at a small increase in its budget, but that could change), the interim paylines will be adjusted upward, and these higher paylines will be retrospective to the beginning of the year. The impact of the NGRI is unclear, as each IC will manage the program however they see fit, but overall, paylines for ESI applicants will continue to be higher than those for established PIs across the NIH. The final ESI paylines won’t be known until the FY18 budget is signed into law, though (NGRI also based on appropriation levels).

Categories: NIH-Funding

By: Unclear about ESI

WriteEdit-Grant Questions Blog - Thu, 10/12/2017 - 16:12

Thanks so much for your site. I am unclear about the Next Generation Researchers Initiative. For example, the NIAID payline for ESI in FY17 was 18th percentile but with the interim FY18 budget the ESI has dropped to 13th percentile. Will this drop in percentile’s for ESI’s is persist or will it be rectified with the Next Generation Initiative? Will this interim budget only adversely affect those whose Council’s met in Sept of 2017? Will this be a trend for other institutes as well?

Categories: NIH-Funding

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Thu, 10/12/2017 - 12:39
Funding Opportunity RFA-EB-17-005 from the NIH Guide for Grants and Contracts. This FOA solicits new theories, computational models, and statistical tools to derive understanding of brain function from complex neuroscience data. Proposed tools could include the creation of new theories, ideas, and conceptual frameworks to organize/unify data and infer general principles of brain function; new computational models to develop testable hypotheses and design/drive experiments; and new mathematical and statistical methods to support or refute a stated hypothesis about brain function, and/or assist in detecting dynamical features and patterns in complex brain data. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to validity testing of the tools being developed.
Categories: NIH-Funding

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp)

NIH Funding Announcements - Thu, 10/12/2017 - 12:21
Funding Opportunity PA-18-314 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products, and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees.
Categories: NIH-Funding

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50)

NIH Funding Announcements - Thu, 10/12/2017 - 11:38
Funding Opportunity PAR-18-313 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.
Categories: NIH-Funding

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 - Clinical Trials Not Allowed)

NIH Funding Announcements - Thu, 10/12/2017 - 03:33
Funding Opportunity PAR-18-317 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.
Categories: NIH-Funding

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed

NIH Funding Announcements - Thu, 10/12/2017 - 03:33
Funding Opportunity PAR-18-310 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.
Categories: NIH-Funding